NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp..
Next-generation anti-oxMIF antibody ON203 demonstrates anti-tumor effects through tumor cell death and modulation of the immunosuppressive tumor microenvironment in human tumoroids isolated from